IN2014DN07509A - - Google Patents
Info
- Publication number
- IN2014DN07509A IN2014DN07509A IN7509DEN2014A IN2014DN07509A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A IN 7509DEN2014 A IN7509DEN2014 A IN 7509DEN2014A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A
- Authority
- IN
- India
- Prior art keywords
- independently
- optionally substituted
- therapy
- halogen
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1204125.7A GB201204125D0 (en) | 2012-03-08 | 2012-03-08 | Compounds |
| PCT/GB2013/050583 WO2013132270A1 (en) | 2012-03-08 | 2013-03-08 | Phosphoinositide 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07509A true IN2014DN07509A (enExample) | 2015-04-24 |
Family
ID=46026238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7509DEN2014 IN2014DN07509A (enExample) | 2012-03-08 | 2013-03-08 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9663487B2 (enExample) |
| EP (1) | EP2822943B1 (enExample) |
| CN (1) | CN104254532A (enExample) |
| GB (1) | GB201204125D0 (enExample) |
| IN (1) | IN2014DN07509A (enExample) |
| WO (1) | WO2013132270A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2467387T3 (pl) | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| NZ707366A (en) | 2012-11-07 | 2018-11-30 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| RS57816B1 (sr) | 2013-05-10 | 2018-12-31 | Karus Therapeutics Ltd | Inhibitori histon deacetilaze |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514758D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| WO2019178079A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CA2407593C (en) | 2000-04-27 | 2011-01-11 | Yamanouchi Pharmaceutical Co. Ltd. | Fused heteroaryl derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CA2414468A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1922171B (zh) | 2004-02-26 | 2012-10-17 | Aska制药株式会社 | 嘧啶衍生物 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| EP2032582A1 (en) | 2006-04-26 | 2009-03-11 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as pi3k inhibitors |
| WO2007127183A1 (en) | 2006-04-26 | 2007-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| US20100216820A1 (en) | 2006-11-13 | 2010-08-26 | White Stephen L | Thienopyrimidiones for treatment of inflammatory disorders and cancers |
| CN101663276A (zh) * | 2007-01-31 | 2010-03-03 | 沃泰克斯药物股份有限公司 | 用作激酶抑制剂的2-氨基吡啶衍生物 |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| WO2008121257A1 (en) | 2007-03-28 | 2008-10-09 | Merck & Co., Inc. | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| WO2010037765A2 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| PL2467387T3 (pl) | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| HUE037645T2 (hu) | 2011-07-27 | 2018-09-28 | Astrazeneca Ab | Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| BR112015011456A2 (pt) | 2012-11-20 | 2017-07-11 | Genentech Inc | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m |
| RS57816B1 (sr) | 2013-05-10 | 2018-12-31 | Karus Therapeutics Ltd | Inhibitori histon deacetilaze |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| JP6584391B2 (ja) | 2013-10-10 | 2019-10-02 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
-
2012
- 2012-03-08 GB GBGB1204125.7A patent/GB201204125D0/en not_active Ceased
-
2013
- 2013-03-08 US US14/382,196 patent/US9663487B2/en not_active Expired - Fee Related
- 2013-03-08 WO PCT/GB2013/050583 patent/WO2013132270A1/en not_active Ceased
- 2013-03-08 EP EP13709523.8A patent/EP2822943B1/en not_active Not-in-force
- 2013-03-08 IN IN7509DEN2014 patent/IN2014DN07509A/en unknown
- 2013-03-08 CN CN201380013216.5A patent/CN104254532A/zh active Pending
-
2017
- 2017-04-25 US US15/496,511 patent/US10035785B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2822943A1 (en) | 2015-01-14 |
| GB201204125D0 (en) | 2012-04-25 |
| EP2822943B1 (en) | 2018-10-03 |
| US20180072699A1 (en) | 2018-03-15 |
| US9663487B2 (en) | 2017-05-30 |
| US10035785B2 (en) | 2018-07-31 |
| CN104254532A (zh) | 2014-12-31 |
| US20150080395A1 (en) | 2015-03-19 |
| WO2013132270A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07509A (enExample) | ||
| CA2875877C (en) | Syk inhibitors | |
| TN2012000401A1 (en) | Heterocyclic compound | |
| NZ705705A (en) | Ret inhibitor | |
| PH12014500599B1 (en) | Protein kinase inhibitors | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| PH12014501719A1 (en) | Pyridone derivatives | |
| UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
| IN2014MN02598A (enExample) | ||
| MY193277A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| PH12013502434A1 (en) | Substituted pyridopyrazines as novel syk inhibitors | |
| GB201209587D0 (en) | Therapeutic compounds | |
| MY172422A (en) | Pyrazole compound and pharmaceutical use thereof | |
| MY170262A (en) | Dicarboxylic acid compound | |
| MX2013005819A (es) | Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. | |
| MX2014015345A (es) | Inhibidores piranopiridona de tanquirasa. | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| PH12013501487A1 (en) | 2-methoxy-pyridin-4-yl derivatives | |
| MX2015002705A (es) | Compuestos de piridinona para usarse en terapia fotodinamica. | |
| CY1117011T1 (el) | Παραγωγα αζολιου | |
| MX358151B (es) | Derivado de sitaxentan. | |
| IN2014CN04922A (enExample) | ||
| MY173812A (en) | 2-pyridone compound |